{"component": "clause", "props": {"groups": [{"snippet": "BMS, its Affiliates and Sublicensees shall be entitled to continue to sell (but not to actively promote after the effective date of termination) any existing inventory of Products in each terminated Region of the Territory for which Regulatory Approval and all pricing and reimbursement approvals therefor have been obtained (provided that such Products shall have launched in each such terminated country as of the applicable effective date of termination), in accordance with the terms and conditions of this Agreement, for a period not to exceed [***] from the effective date of such termination (the \u201cCommercialization Wind-Down Period\u201d). Any Products sold or disposed of by BMS, its Affiliates or Sublicensees during the Commercialization Wind-Down Period shall be subject to the same Total Compensation under Section 8.5 as would have applied had this Agreement otherwise remained in force and effect with respect to such terminated Product(s) and terminated Region(s). After the Commercialization Wind-Down Period, BMS, its Affiliates and Sublicensees shall not sell such terminated Products in such terminated Region(s) or make any representation regarding BMS\u2019s status as a licensee of such Product in such Region(s). Either (i) at the request of BN at the end of the Commercialization Wind-Down Period or (ii) prior to the end of the Commercialization Wind-Down Period, if BN has assumed responsibilities for regulatory activities under the Regulatory Approval, has received all clearances and Regulatory Approvals needed to sell and import the terminated Product in a given terminated country, and provides written notice to BMS that it wishes to assume sale of the terminated Product in a terminated country, then, in either case (i) or (ii), at BN\u2019s election, BMS shall sell and transfer to BN such portion of the terminated Product inventory then held by BMS or its Affiliates which is in a saleable condition (including that it is undamaged, has been stored in proper conditions and has no less than [***] shelf-life remaining) as had been allocated to the terminated Region(s) [***]. This Section 12.7(b) shall not apply in the case of termination by BMS under Section 12.2(b) based on Safety Reasons.", "size": 32, "snippet_links": [{"key": "affiliates-and-sublicensees", "type": "clause", "offset": [9, 36]}, {"key": "to-sell", "type": "clause", "offset": [67, 74]}, {"key": "actively-promote", "type": "definition", "offset": [87, 103]}, {"key": "effective-date-of-termination", "type": "definition", "offset": [114, 143]}, {"key": "existing-inventory-of-products", "type": "clause", "offset": [149, 179]}, {"key": "terminated-region", "type": "definition", "offset": [188, 205]}, {"key": "the-territory", "type": "clause", "offset": [209, 222]}, {"key": "pricing-and-reimbursement-approvals", "type": "clause", "offset": [261, 296]}, {"key": "provided-that", "type": "definition", "offset": [326, 339]}, {"key": "terminated-country", "type": "definition", "offset": [387, 405]}, {"key": "applicable-effective-date", "type": "definition", "offset": [416, 441]}, {"key": "in-accordance-with", "type": "definition", "offset": [459, 477]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [482, 520]}, {"key": "not-to-exceed", "type": "clause", "offset": [535, 548]}, {"key": "from-the-effective-date", "type": "clause", "offset": [555, 578]}, {"key": "products-sold", "type": "clause", "offset": [647, 660]}, {"key": "disposed-of", "type": "definition", "offset": [664, 675]}, {"key": "subject-to-the", "type": "definition", "offset": [770, 784]}, {"key": "total-compensation", "type": "definition", "offset": [790, 808]}, {"key": "section-85", "type": "clause", "offset": [815, 826]}, {"key": "force-and-effect", "type": "clause", "offset": [890, 906]}, {"key": "with-respect-to", "type": "clause", "offset": [907, 922]}, {"key": "terminated-products", "type": "clause", "offset": [1079, 1098]}, {"key": "the-request", "type": "clause", "offset": [1241, 1252]}, {"key": "of-bn", "type": "clause", "offset": [1253, 1258]}, {"key": "at-the-end-of-the", "type": "clause", "offset": [1259, 1276]}, {"key": "prior-to-the", "type": "clause", "offset": [1320, 1332]}, {"key": "activities-under", "type": "clause", "offset": [1430, 1446]}, {"key": "regulatory-approvals", "type": "clause", "offset": [1504, 1524]}, {"key": "notice-to", "type": "clause", "offset": [1626, 1635]}, {"key": "to-assume", "type": "clause", "offset": [1655, 1664]}, {"key": "sale-of-the", "type": "clause", "offset": [1665, 1676]}, {"key": "transfer-to", "type": "clause", "offset": [1792, 1803]}, {"key": "product-inventory", "type": "definition", "offset": [1838, 1855]}, {"key": "proper-conditions", "type": "clause", "offset": [1976, 1993]}, {"key": "life-remaining", "type": "clause", "offset": [2027, 2041]}, {"key": "allocated-to", "type": "definition", "offset": [2055, 2067]}, {"key": "in-the-case", "type": "clause", "offset": [2137, 2148]}, {"key": "termination-by-bms", "type": "clause", "offset": [2152, 2170]}, {"key": "based-on", "type": "definition", "offset": [2193, 2201]}, {"key": "safety-reasons", "type": "definition", "offset": [2202, 2216]}], "samples": [{"hash": "jI99aQtPFmS", "uri": "/contracts/jI99aQtPFmS#commercialization", "label": "Option and License Agreement (Bavarian Nordic a/S / ADR)", "score": 27.0287475586, "published": true}, {"hash": "dSX50AVcRkN", "uri": "/contracts/dSX50AVcRkN#commercialization", "label": "Option and License Agreement (Bavarian Nordic a/S / ADR)", "score": 27.0068454742, "published": true}, {"hash": "i83DCPzMfAC", "uri": "/contracts/i83DCPzMfAC#commercialization", "label": "Option and License Agreement (Bavarian Nordic a/S / ADR)", "score": 26.856262207, "published": true}], "hash": "0d710f9840e866523bc2b3982a097673", "id": 2}, {"snippet": "Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.", "size": 42, "snippet_links": [{"key": "right-to-develop", "type": "clause", "offset": [24, 40]}, {"key": "reverted-products", "type": "definition", "offset": [63, 80]}, {"key": "third-parties", "type": "clause", "offset": [108, 121]}, {"key": "obligation-to", "type": "clause", "offset": [157, 170]}, {"key": "in-connection-with", "type": "clause", "offset": [207, 225]}], "samples": [{"hash": "FqP4X806I2", "uri": "/contracts/FqP4X806I2#commercialization", "label": "Exclusive Channel Collaboration Agreement (Castle Creek Biosciences, Inc.)", "score": 32.5373039246, "published": true}, {"hash": "21YulHc3wiS", "uri": "/contracts/21YulHc3wiS#commercialization", "label": "Exclusive Channel Collaboration Agreement (Castle Creek Biosciences, Inc.)", "score": 32.4031486511, "published": true}, {"hash": "8i1U69YSon0", "uri": "/contracts/8i1U69YSon0#commercialization", "label": "Exclusive Channel Collaboration Agreement (Fibrocell Science, Inc.)", "score": 27.0068454742, "published": true}], "hash": "fdf25d2c49bdaa1af60dd0a8f396c0f5", "id": 1}, {"snippet": "Licensee shall promote, Commercialize and sell the Licensed Product in strict adherence to regulatory, professional, and legal requirements in the Territory and solely to the extent permitted under, and consistent with, all applicable regulatory approvals (including, without limitation, Key Approvals). In no event shall Licensee, directly or indirectly, promote, market, offer for sale, sell, donate or otherwise distribute the Licensed Product for any use outside of the Field or otherwise perform any off-label promotion, marketing or Commercialization of the Licensed Product. Licensee shall do nothing which would jeopardize the good will or reputation of MPP or Pfizer or the reputation of the Compound, Product and/or Licensed Product.", "size": 31, "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "strict-adherence", "type": "clause", "offset": [71, 87]}, {"key": "legal-requirements", "type": "definition", "offset": [121, 139]}, {"key": "in-the-territory", "type": "clause", "offset": [140, 156]}, {"key": "to-the-extent", "type": "clause", "offset": [168, 181]}, {"key": "consistent-with", "type": "clause", "offset": [203, 218]}, {"key": "applicable-regulatory-approvals", "type": "definition", "offset": [224, 255]}, {"key": "without-limitation", "type": "clause", "offset": [268, 286]}, {"key": "key-approvals", "type": "clause", "offset": [288, 301]}, {"key": "in-no-event-shall", "type": "clause", "offset": [304, 321]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [332, 354]}, {"key": "offer-for-sale", "type": "clause", "offset": [373, 387]}, {"key": "distribute-the", "type": "clause", "offset": [415, 429]}, {"key": "outside-of-the-field", "type": "clause", "offset": [459, 479]}, {"key": "commercialization-of-the-licensed-product", "type": "clause", "offset": [539, 580]}, {"key": "good-will", "type": "definition", "offset": [635, 644]}], "samples": [{"hash": "9UKSM6MoXOX", "uri": "/contracts/9UKSM6MoXOX#commercialization", "label": "License Agreement", "score": 33.493347168, "published": true}, {"hash": "8BTiZcAhKvm", "uri": "/contracts/8BTiZcAhKvm#commercialization", "label": "License Agreement", "score": 33.2059211731, "published": true}, {"hash": "8Dy7Yg2U5Ry", "uri": "/contracts/8Dy7Yg2U5Ry#commercialization", "label": "License Agreement", "score": 33.1785469055, "published": true}], "hash": "27cf9b69f089244e8f6987eeff7d67a4", "id": 3}, {"snippet": "Sellers shall have no responsibility for any aspects of Development or Commercialization of the Products, including planning and implementation, distribution, booking of sales, pricing or reimbursement.", "size": 9, "snippet_links": [{"key": "responsibility-for", "type": "clause", "offset": [22, 40]}, {"key": "commercialization-of-the-products", "type": "clause", "offset": [71, 104]}, {"key": "planning-and-implementation", "type": "clause", "offset": [116, 143]}, {"key": "booking-of-sales", "type": "clause", "offset": [159, 175]}], "samples": [{"hash": "kb2KwWnhafZ", "uri": "/contracts/kb2KwWnhafZ#commercialization", "label": "Asset Purchase Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}, {"hash": "iD9GfsDaOI8", "uri": "/contracts/iD9GfsDaOI8#commercialization", "label": "Asset Purchase Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}, {"hash": "1ZGQlyyZwNY", "uri": "/contracts/1ZGQlyyZwNY#commercialization", "label": "Asset Purchase Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}], "hash": "06f506fc4da21a5d2d747a05107bd748", "id": 7}, {"snippet": "To avoid a disruption in the supply of Products to patients, if the Agreement is terminated after the first commercial sale of any Product in the Territory, Cephalon, its Affiliates and its Marketing Partners shall continue to distribute the Products in each country of the Territory for which Marketing Approval therefor has been obtained, in accordance with the terms and conditions of this Agreement, until the date on which Angioblast notifies Cephalon in writing that Angioblast has secured an alternative distributor or licensee for the Products in such country, but in no event more for than twenty-four (24) months after the effective date of any termination of this Agreement, in whole or in part (the \u201cWind-down Period\u201d); provided that Cephalon, its Affiliates and its Marketing Partners shall cease such activities, or any portion thereof, in a given country upon sixty (60) days\u2019 notice by Angioblast requesting that such activities (or portion thereof) be ceased. Notwithstanding any other provision of this Agreement, during the Wind-down Period, Cephalon\u2019s and its Affiliates\u2019 and Marketing Partners\u2019 rights with respect to the Products in the Territory shall be non-exclusive and, without limiting the foregoing, Angioblast shall have the right to engage one or more other distributor(s) and/or licensee(s) of any Products in all or part of the Territory. Any Products sold or disposed by Cephalon in the Territory during the Wind-down Period shall be subject to applicable payment obligations under ARTICLE VI above. Within thirty (30) days of expiration of the Wind-down Period, Cephalon shall, upon the request of Angioblast, transfer to Angioblast or its designee, all Products and BMT MPCs in its inventory at the provisional transfer price therefor (as set forth in Paragraph 2(c) of Exhibit 6.3).", "size": 10, "snippet_links": [{"key": "supply-of-products", "type": "clause", "offset": [29, 47]}, {"key": "the-agreement", "type": "clause", "offset": [64, 77]}, {"key": "sale-of", "type": "clause", "offset": [119, 126]}, {"key": "in-the-territory", "type": "clause", "offset": [139, 155]}, {"key": "marketing-partners", "type": "clause", "offset": [190, 208]}, {"key": "the-products", "type": "clause", "offset": [238, 250]}, {"key": "marketing-approval", "type": "definition", "offset": [294, 312]}, {"key": "in-accordance-with", "type": "definition", "offset": [341, 359]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [364, 402]}, {"key": "in-writing", "type": "definition", "offset": [457, 467]}, {"key": "in-no-event", "type": "clause", "offset": [573, 584]}, {"key": "date-of", "type": "clause", "offset": [643, 650]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [655, 684]}, {"key": "provided-that", "type": "definition", "offset": [732, 745]}, {"key": "notice-by", "type": "clause", "offset": [892, 901]}, {"key": "other-provision-of-this-agreement", "type": "clause", "offset": [997, 1030]}, {"key": "with-respect-to", "type": "clause", "offset": [1123, 1138]}, {"key": "territory-shall", "type": "definition", "offset": [1159, 1174]}, {"key": "without-limiting-the-foregoing", "type": "clause", "offset": [1197, 1227]}, {"key": "right-to", "type": "definition", "offset": [1255, 1263]}, {"key": "products-sold", "type": "clause", "offset": [1376, 1389]}, {"key": "subject-to", "type": "definition", "offset": [1468, 1478]}, {"key": "payment-obligations", "type": "definition", "offset": [1490, 1509]}, {"key": "article-vi", "type": "definition", "offset": [1516, 1526]}, {"key": "within-thirty", "type": "clause", "offset": [1534, 1547]}, {"key": "expiration-of-the", "type": "clause", "offset": [1561, 1578]}, {"key": "the-request", "type": "clause", "offset": [1618, 1629]}, {"key": "transfer-to", "type": "clause", "offset": [1645, 1656]}, {"key": "all-products", "type": "clause", "offset": [1685, 1697]}, {"key": "bmt-mpcs", "type": "definition", "offset": [1702, 1710]}, {"key": "provisional-transfer-price", "type": "definition", "offset": [1735, 1761]}], "samples": [{"hash": "e7Z7WxhFecw", "uri": "/contracts/e7Z7WxhFecw#commercialization", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 26.7193698883, "published": true}, {"hash": "hgoBviDMJyR", "uri": "/contracts/hgoBviDMJyR#commercialization", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 25.9390830994, "published": true}, {"hash": "8Y3QglFoAQk", "uri": "/contracts/8Y3QglFoAQk#commercialization", "label": "Development and Commercialization Agreement (Cephalon Inc)", "score": 22.338809967, "published": true}], "hash": "e4775cac650d80a3e51a22434b965765", "id": 6}, {"snippet": "Provided that the termination of this Agreement is not a termination by Galderma pursuant to Section 12.2.4, if requested by NovaBay, Galderma and its Affiliates and Marketing Partners shall continue to distribute and sell Collaboration Products in the Field in each country of the Galderma Territory for which Marketing Approval therefor has been obtained, in accordance with the terms and conditions of this Agreement, for a period requested by NovaBay not to exceed two (2) years from the effective date of such expiration or termination (for purposes of this Section 12.6.3, the Agreement Wind-Down Period); provided that NovaBay may terminate the Agreement Wind-Down Period upon sixty (60) days\u2019 notice to Galderma. Notwithstanding any other provision of this Agreement, during the Agreement Wind-Down Period, Galderma\u2019s, its Affiliates\u2019 and its Marketing Partners\u2019 rights with respect to Collaboration Products (including the licenses granted under Section 7.1.1) shall be non-exclusive and NovaBay shall have the right to engage one or more other partner(s) or distributor(s) of Collaboration Products in the Field in all or part of the Galderma Territory. Any Collaboration Products sold or disposed by Galderma or its Affiliates or Marketing Partners during the Agreement Wind-Down Period shall be subject to the applicable royalties under Section 8.5. After the Agreement Wind-Down Period, Galderma and its Affiliates and Marketing Partners shall not make any representation regarding their status as a licensee of or distributor for NovaBay for any Collaboration Product. In addition, Galderma shall promptly provide NovaBay copies of customer lists and other customer information relating to Collaboration Products reasonably necessary in Galderma\u2019s reasonable opinion for NovaBay to continue to Commercialize such Collaboration Products, which NovaBay shall have the right to use and disclose for any purpose during the Agreement Wind-Down Period and thereafter. ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.", "size": 11, "snippet_links": [{"key": "provided-that", "type": "definition", "offset": [0, 13]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [18, 47]}, {"key": "termination-by", "type": "clause", "offset": [57, 71]}, {"key": "pursuant-to-section", "type": "definition", "offset": [81, 100]}, {"key": "requested-by", "type": "definition", "offset": [112, 124]}, {"key": "marketing-partners", "type": "clause", "offset": [166, 184]}, {"key": "to-distribute", "type": "definition", "offset": [200, 213]}, {"key": "collaboration-products", "type": "definition", "offset": [223, 245]}, {"key": "in-the-field", "type": "clause", "offset": [246, 258]}, {"key": "galderma-territory", "type": "definition", "offset": [282, 300]}, {"key": "marketing-approval", "type": "definition", "offset": [311, 329]}, {"key": "in-accordance-with", "type": "definition", "offset": [358, 376]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [381, 419]}, {"key": "not-to-exceed", "type": "clause", "offset": [455, 468]}, {"key": "date-of", "type": "clause", "offset": [502, 509]}, {"key": "expiration-or-termination", "type": "clause", "offset": [515, 540]}, {"key": "section-1263", "type": "clause", "offset": [563, 577]}, {"key": "terminate-the-agreement", "type": "clause", "offset": [638, 661]}, {"key": "notice-to", "type": "clause", "offset": [701, 710]}, {"key": "other-provision-of-this-agreement", "type": "clause", "offset": [741, 774]}, {"key": "with-respect-to", "type": "clause", "offset": [878, 893]}, {"key": "licenses-granted", "type": "clause", "offset": [932, 948]}, {"key": "section-711", "type": "clause", "offset": [955, 968]}, {"key": "the-right", "type": "clause", "offset": [1016, 1025]}, {"key": "products-sold", "type": "clause", "offset": [1182, 1195]}, {"key": "applicable-royalties", "type": "clause", "offset": [1322, 1342]}, {"key": "section-85", "type": "clause", "offset": [1349, 1360]}, {"key": "after-the-agreement", "type": "clause", "offset": [1362, 1381]}, {"key": "in-addition", "type": "clause", "offset": [1583, 1594]}, {"key": "promptly-provide", "type": "clause", "offset": [1611, 1627]}, {"key": "customer-lists", "type": "definition", "offset": [1646, 1660]}, {"key": "customer-information", "type": "definition", "offset": [1671, 1691]}, {"key": "relating-to", "type": "definition", "offset": [1692, 1703]}, {"key": "reasonably-necessary", "type": "clause", "offset": [1727, 1747]}, {"key": "to-commercialize", "type": "definition", "offset": [1805, 1821]}, {"key": "right-to-use", "type": "clause", "offset": [1880, 1892]}, {"key": "confidential-treatment-requested", "type": "clause", "offset": [1979, 2011]}, {"key": "pursuant-to-a", "type": "definition", "offset": [2012, 2025]}, {"key": "request-for-confidential-treatment", "type": "definition", "offset": [2026, 2060]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [2072, 2110]}, {"key": "the-commission", "type": "clause", "offset": [2161, 2175]}], "samples": [{"hash": "i8HfOlNMXSL", "uri": "/contracts/i8HfOlNMXSL#commercialization", "label": "Collaboration and License Agreement (NovaBay Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "85DTVnAO3be", "uri": "/contracts/85DTVnAO3be#commercialization", "label": "Collaboration and License Agreement (NovaBay Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "hash": "a38bb93ed2ca6d31dcd81a938c705cca", "id": 5}, {"snippet": "Ikaria shall be solely responsible for conducting, itself or through Affiliates or Licensees, the Commercialization of Products in the Field in the Territory, including (a) contracting with customers and booking sales, (b) setting the price and terms and conditions under which a Product may be sold to customers, and (c) handling of managed care accounts, and, subject to Section 1.29, Section 4.2(b), Section 5.2(d), Section 5.3(e) and Section 10.1(b), as between the Parties, Ikaria shall bear all costs associated therewith. Ikaria shall produce and update from time to time a comprehensive Commercialization plan (the \u201cCommercialization Plan\u201d), which shall include plans for Commercializing Product in each major market in which Ikaria does not then have a presence. The Commercialization Plan shall include a preliminary timeline for the initial Commercialization of Products, which is intended as a planning and informational tool and shall not constitute a binding obligation on Ikaria, and shall be subject to adjustment by Ikaria from time to time, provided, that, Ikaria shall provide BioLineRx with prior written notice of any material proposed change to a timeline. The most recent preliminary Commercialization Plan is attached hereto as Schedule 3.7.", "size": 8, "snippet_links": [{"key": "responsible-for", "type": "clause", "offset": [23, 38]}, {"key": "commercialization-of-products", "type": "clause", "offset": [98, 127]}, {"key": "in-the-field", "type": "clause", "offset": [128, 140]}, {"key": "in-the-territory", "type": "clause", "offset": [141, 157]}, {"key": "contracting-with", "type": "clause", "offset": [173, 189]}, {"key": "booking-sales", "type": "clause", "offset": [204, 217]}, {"key": "conditions-under-which", "type": "clause", "offset": [255, 277]}, {"key": "sold-to", "type": "clause", "offset": [295, 302]}, {"key": "managed-care", "type": "definition", "offset": [334, 346]}, {"key": "subject-to-section", "type": "clause", "offset": [362, 380]}, {"key": "between-the-parties", "type": "clause", "offset": [458, 477]}, {"key": "all-costs", "type": "definition", "offset": [497, 506]}, {"key": "from-time-to-time", "type": "clause", "offset": [561, 578]}, {"key": "commercialization-plan", "type": "clause", "offset": [595, 617]}, {"key": "plans-for", "type": "clause", "offset": [670, 679]}, {"key": "major-market", "type": "definition", "offset": [712, 724]}, {"key": "initial-commercialization", "type": "definition", "offset": [844, 869]}, {"key": "binding-obligation", "type": "definition", "offset": [965, 983]}, {"key": "by-ikaria", "type": "clause", "offset": [1030, 1039]}, {"key": "notice-of-any", "type": "clause", "offset": [1125, 1138]}, {"key": "change-to", "type": "clause", "offset": [1157, 1166]}, {"key": "most-recent", "type": "definition", "offset": [1183, 1194]}], "samples": [{"hash": "aqqfj3FR3dp", "uri": "/contracts/aqqfj3FR3dp#commercialization", "label": "License and Commercialization Agreement (Bellerophon Therapeutics, Inc.)", "score": 26.2429847717, "published": true}, {"hash": "642nEY2fakH", "uri": "/contracts/642nEY2fakH#commercialization", "label": "License and Commercialization Agreement (BioLineRx Ltd.)", "score": 26.22108078, "published": true}, {"hash": "eqgtMpj78Xc", "uri": "/contracts/eqgtMpj78Xc#commercialization", "label": "License and Commercialization Agreement (Bellerophon Therapeutics LLC)", "score": 26.032169342, "published": true}], "hash": "5dc95560ec50f0d56a2c1a7e4ce5f4aa", "id": 10}, {"snippet": "Licensee agrees to use its best efforts to commercially introduce its first Licensed Product in the Field as soon as practicable. Licensee shall be deemed to have satisfied its obligations under this Section 7.1 if Licensee has an ongoing and active research, development or marketing program, directed primarily toward commercial production and use of its first Licensed Product. Any efforts of Licensee\u2019s Affiliates or sublicensees shall be considered efforts of Licensee for the sole purpose of determining Licensee\u2019s compliance with its obligation under this Section 7.1.", "size": 9, "snippet_links": [{"key": "licensee-agrees-to", "type": "clause", "offset": [0, 18]}, {"key": "best-efforts", "type": "clause", "offset": [27, 39]}, {"key": "first-licensed-product", "type": "definition", "offset": [70, 92]}, {"key": "in-the-field", "type": "clause", "offset": [93, 105]}, {"key": "as-soon-as-practicable", "type": "definition", "offset": [106, 128]}, {"key": "licensee-shall", "type": "clause", "offset": [130, 144]}, {"key": "section-71", "type": "definition", "offset": [200, 211]}, {"key": "marketing-program", "type": "definition", "offset": [275, 292]}, {"key": "commercial-production", "type": "definition", "offset": [320, 341]}, {"key": "of-licensee", "type": "clause", "offset": [393, 404]}, {"key": "purpose-of", "type": "clause", "offset": [487, 497]}, {"key": "compliance-with", "type": "clause", "offset": [521, 536]}], "samples": [{"hash": "3NMJgMPJdCf", "uri": "/contracts/3NMJgMPJdCf#commercialization", "label": "License Agreement (Gevo, Inc.)", "score": 21.8405208588, "published": true}, {"hash": "4ezsMpU0uEv", "uri": "/contracts/4ezsMpU0uEv#commercialization", "label": "License Agreement (Gevo, Inc.)", "score": 21.61054039, "published": true}], "hash": "629110b8abae88619f91209d1088405f", "id": 9}, {"snippet": "If this Agreement is terminated after the First Commercial Sale of a Terminated Denali Product in the Terminated Area, Sanofi, its Affiliates and its Sublicensees shall continue to fulfill orders for the Terminated Area through their respective then-existing distribution network of internal and external distributors of such Terminated Denali Product, in accordance with the terms and conditions of this Agreement, in each country for which Regulatory Approval therefor has been obtained, for [***] after the effective date of termination (\u201cCommercialization Wind-down Period\u201d); [***]; provided, further, that Sanofi, its Affiliates and its Sublicensees shall cease any such activities being conducted pursuant to this Section (f)(ii), or any portion thereof, in a given country within the Terminated Area upon [***] notice by Denali requesting that such activities (or portion thereof) be ceased. Notwithstanding any other provision of this Agreement, during the Commercialization Wind-down Period, Sanofi\u2019s and its Affiliates\u2019 and Sublicensees\u2019 rights with respect to applicable Terminated Denali Product(s) in the Terminated Area shall be non-exclusive and, without limiting the foregoing, Denali shall have the right to engage one or more other distributor(s) or licensee(s) of such Terminated Denali Product(s) in any country within the Terminated Area. Any Terminated Denali Product sold or disposed of by Sanofi, its Affiliates or its Sublicensees in any country within the Terminated Area during the Commercialization Wind-down Period shall be subject to applicable payment obligations under Article 7 (Payments). In addition, if at the effective time of such termination, Sanofi or its Affiliates are undertaking Detailing or MSL Activities with respect to a particular Terminated Denali Product in any country within the Terminated Area, then, at Denali\u2019s request, the Parties will negotiate and agree upon a plan for the orderly wind down of such activities for a period not to exceed [***]. Any FTE Costs or Out-of-Pocket Costs incurred by Sanofi or its Affiliates in accordance with such plan for the wind down of Sanofi\u2019s activities shall be (a) reimbursed by Denali if the relevant Terminated Denali Product is not, immediately prior to the effective date of such termination, a Cost Profit Sharing Product; or (b) continue to be allocated towards Allowable Expenses until such wind down is complete, if the relevant Terminated Denali Product is a Cost Profit Sharing Product immediately prior to the effective date of such termination.", "size": 13, "snippet_links": [{"key": "sale-of", "type": "clause", "offset": [59, 66]}, {"key": "distribution-network", "type": "definition", "offset": [259, 279]}, {"key": "in-accordance-with", "type": "definition", "offset": [353, 371]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [376, 414]}, {"key": "regulatory-approval", "type": "definition", "offset": [442, 461]}, {"key": "effective-date-of-termination", "type": "definition", "offset": [510, 539]}, {"key": "being-conducted", "type": "definition", "offset": [687, 702]}, {"key": "pursuant-to", "type": "definition", "offset": [703, 714]}, {"key": "notice-by", "type": "clause", "offset": [818, 827]}, {"key": "other-provision-of-this-agreement", "type": "clause", "offset": [919, 952]}, {"key": "with-respect-to", "type": "clause", "offset": [1055, 1070]}, {"key": "without-limiting-the-foregoing", "type": "clause", "offset": [1162, 1192]}, {"key": "right-to", "type": "definition", "offset": [1216, 1224]}, {"key": "disposed-of", "type": "definition", "offset": [1398, 1409]}, {"key": "by-sanofi", "type": "clause", "offset": [1410, 1419]}, {"key": "subject-to", "type": "definition", "offset": [1553, 1563]}, {"key": "payment-obligations", "type": "definition", "offset": [1575, 1594]}, {"key": "article-7", "type": "definition", "offset": [1601, 1610]}, {"key": "in-addition", "type": "clause", "offset": [1623, 1634]}, {"key": "at-the-effective-time", "type": "clause", "offset": [1639, 1660]}, {"key": "msl-activities", "type": "definition", "offset": [1736, 1750]}, {"key": "the-parties-will", "type": "clause", "offset": [1876, 1892]}, {"key": "wind-down", "type": "definition", "offset": [1941, 1950]}, {"key": "not-to-exceed", "type": "clause", "offset": [1983, 1996]}, {"key": "fte-costs", "type": "clause", "offset": [2008, 2017]}, {"key": "costs-incurred", "type": "definition", "offset": [2035, 2049]}, {"key": "the-relevant", "type": "clause", "offset": [2185, 2197]}, {"key": "prior-to-the-effective-date", "type": "clause", "offset": [2244, 2271]}, {"key": "profit-sharing", "type": "definition", "offset": [2300, 2314]}, {"key": "allowable-expenses", "type": "clause", "offset": [2364, 2382]}], "samples": [{"hash": "1O9capFL2p9", "uri": "/contracts/1O9capFL2p9#commercialization", "label": "Collaboration and License Agreement (Denali Therapeutics Inc.)", "score": 30.1909656525, "published": true}], "hash": "ac218b553d22e33f3896c32c421ae711", "id": 4}, {"snippet": "The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company\u2019s sole discretion and for the Company\u2019s sole benefit and that no royalty or other consideration will be due or payable to him as a result of the Company\u2019s efforts to commercialize or market any such Work Product.", "size": 9, "snippet_links": [{"key": "the-executive", "type": "clause", "offset": [0, 13]}, {"key": "the-decision", "type": "clause", "offset": [31, 43]}, {"key": "to-commercialize", "type": "definition", "offset": [59, 75]}, {"key": "work-product", "type": "clause", "offset": [90, 102]}, {"key": "sole-discretion", "type": "definition", "offset": [127, 142]}, {"key": "for-the-company", "type": "definition", "offset": [147, 162]}, {"key": "sole-benefit", "type": "definition", "offset": [165, 177]}, {"key": "no-royalty", "type": "clause", "offset": [187, 197]}, {"key": "other-consideration", "type": "definition", "offset": [201, 220]}, {"key": "payable-to", "type": "definition", "offset": [236, 246]}, {"key": "of-the-company", "type": "clause", "offset": [263, 277]}], "samples": [{"hash": "iNJ6ONKIKi6", "uri": "/contracts/iNJ6ONKIKi6#commercialization", "label": "Executive Employment Agreement (InMed Pharmaceuticals Inc.)", "score": 35.1054077148, "published": true}, {"hash": "c5BxE6dgEtQ", "uri": "/contracts/c5BxE6dgEtQ#commercialization", "label": "Executive Employment Agreement (InMed Pharmaceuticals Inc.)", "score": 33.5475692749, "published": true}, {"hash": "jiTGod40oHF", "uri": "/contracts/jiTGod40oHF#commercialization", "label": "Executive Employment Agreement (InMed Pharmaceuticals Inc.)", "score": 32.5290908813, "published": true}], "hash": "0f907193e94c04b15933aace49de8324", "id": 8}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihpjb21tZXJjaWFsaXphdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"children": [["general", "General"], ["diligence", "Diligence"], ["commercialization-reports", "Commercialization Reports"], ["commercialization-plan", "Commercialization Plan"], ["commercial-diligence", "Commercial Diligence"]], "title": "Commercialization", "parents": [["development-and-commercialization", "Development and Commercialization"], ["effect-of-termination", "Effect of Termination"], ["commercialization", "Commercialization"], ["term-termination", "Term Termination"], ["development-manufacture-and-registration", "Development Manufacture and Registration"]], "size": 2093, "id": "commercialization", "related": [["development-and-commercialization", "Development and Commercialization", "Development and <strong>Commercialization</strong>"], ["commercialization-license", "Commercialization License", "<strong>Commercialization</strong> License"], ["commercialization-plan", "Commercialization Plan", "<strong>Commercialization</strong> Plan"], ["development-activities", "Development Activities", "Development Activities"], ["licensed-product", "Licensed Product", "Licensed Product"]], "related_snippets": [], "updated": "2026-04-26T05:39:20+00:00"}, "json": true, "cursor": ""}}